What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single intravenous (IV) infusion of ATI-1013, 0.2 g total dose.”In the company’s words, NCT07215923 on ClinicalTrials.gov
- Main trialPhase 1
- “This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the body, does drug ATI-1013 trigger an immune response, and the effects of drug ATI-1013 on nicotine levels within the body. The clinical trial will compare drug ATI-1013 to a placebo (a look-alike substance that contains no drug) to see if drug ATI-1013 has comparable safety. Participants will have a Screening visit (Day -28 to -3) and will be admitted on Day -2. Each…”In the company’s words, NCT07215923 on ClinicalTrials.gov
Other drugs for Thromboangiitis Obliterans (Buerger's Disease)
- StempeucelCell Biopeutics Resources Sdn Bhd · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jun 2026 | A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026